Rottapharm Biotech

Focus: Rottapharm Biotech is an Italy-based biotech company focused on small molecules and monoclonal antibodies with a pipeline concentrated in neurology, oncology, and rheumatology.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Rottapharm Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Rottapharm Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PVA Hydrogel

Knee Osteoarthritis

N/A

Clinical Trials (1)

NCT04693104Intra-articular PVA Hydrogel in Knee Osteoarthritis

N/A

Help build intelligence for Rottapharm Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech with pipeline diversity across oncology (CR6086 in colorectal cancer), rheumatology (CR6086 Phase 2), and vaccine development (COVID-eVax)
European-based operations may offer work environment alternatives to traditional US pharma hubs
Opportunity to contribute to multiple therapeutic modalities (small molecules, monoclonals, hydrogel devices) with different risk/reward profiles

Watch Out For

No active job openings posted; limited or no current hiring activity signals potential early-stage constraints or limited expansion
Minimal clinical trial activity (only 2 trials active) and no publications indicate early development stage with limited de-risking data in public domain
No disclosed revenue, funding, or financial information creates visibility gap on runway and long-term stability

Generated by Claude from Rottapharm Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

COVID-eVax

COVID-19

Phase 1/2

CR6086

Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Phase 2

Clinical Trials (1)

NCT03163966A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

Phase 2